First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

BACKGROUND: Fibroblast growth factor receptor (FGFR) 2 is overexpressed in several tumor types, including triple-negative breast cancer and gastric cancer, both of which have a high unmet medical need. Aprutumab ixadotin (BAY 1187982) is the first antibody–drug conjugate (ADC) to target FGFR2 and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sung-Bae, Meric-Bernstam, Funda, Kalyan, Aparna, Babich, Aleksei, Liu, Rong, Tanigawa, Takahiko, Sommer, Anette, Osada, Motonobu, Reetz, Frank, Laurent, Dirk, Wittemer-Rump, Sabine, Berlin, Jordan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797631/
https://www.ncbi.nlm.nih.gov/pubmed/31502117
http://dx.doi.org/10.1007/s11523-019-00670-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797631/
https://www.ncbi.nlm.nih.gov/pubmed/31502117
http://dx.doi.org/10.1007/s11523-019-00670-4

Ejemplares similares